Folate metabolism is the target of methotrexate (MTX) and 5-fluorouracil. Recently, a number of common genetic polymorphisms in folate metabolism with established impact on protein function have been described. The evaluation of genetic variation in folate-metabolizing enzymes may help to identify patients at greater risk for adverse reactions to antifolate drugs. 1 We have previously reported that the 5,10-methylenetetrahydrofolate reductase (MTHFR) 677TT genotype confers increased oral mucositis among patients receiving MTX for immunosuppression and prevention of graft-versus-host disease following hematopoietic-cell-transplantation (HCT). 2 We have expanded the size of the study cohort and investigated now four polymorphisms in key proteins in folate metabolism in relation to oral mucositis among HCT patients: the MTHFR C677T and A1298C polymorphisms and also the 5 0 -28 bp repeat (TSER) and 3 0 UTR 6bp deletion (TS 1494del6) polymorphisms in the thymidylate synthase (TS) gene. Patients with the variant alleles of these polymorphisms have reduced MTHFR activity or TS gene expression or mRNA stability. 1, 3 Adult patients receiving myeloablative allogeneic HCT for chronic myelogenous leukemia (chronic or accelerated phases at transplant) between 1992 and 2002 comprised the study population. The cohort was restricted to patients receiving all four scheduled doses of MTX and no leucovorin rescue. DNA and oral mucositis index (OMI) scores were available for 172 patients meeting eligibility criteria. MTHFR and TS genotypes were determined by PCR/RFLP or allelic discrimination methods as previously described. 4, 5 Mucositis is an important toxicity of folate antagonists, augmenting the mucositis induced by conditioning regimen in the hematopoietic transplant setting. The OMI measures severity of oral mucositis and is assessed at the FHCRC every 2-3 days post transplant. 6 Multivariate linear-regression models (adjusted for conditioning regimen (busulfan/cyclophosphamide or cyclophosphamide/total body irradiation), total MTX dose, age, sex, height, and weight) were used to assess relationships between MTHFR and TS genotypes and mean OMI scores during days 1-18 (overall mucositis course) or 6-12 (peak period of oral mucositis). The study received IRB approval and patients provided informed consent.
Characteristics of the study population were similar to those previously described. 2, 4 Patients with lower MTHFR activity (677TT genotype) experienced about 40% higher mean OMI during days 1-18 compared with the 677CC wildtype genotype (P ¼ 0.02, Table 1 ). A significant trend towards greater mucositis with more copies of the variant 677T allele was observed (P-trend ¼ 0.02). The MTHFR A1298C polymorphism showed a statistically significant trend towards decreased OMI with more copies of the variant 1298C allele (P-trend ¼ 0.049) (top row Table 1 ). However, the two MTHFR polymorphisms are in high linkage disequilibrium. An analysis of the combined MTHFR C677T and A1298C genotypes showed no alteration in risk with MTHFR A1298C on a MTHFR 677CC (wildtype) background, whereas the MTHFR C677T genotype remained a strong predictor of oral mucositis in the analysis of combined genotypes (Table 1) . These results illustrate the need to evaluate both polymorphisms concurrently to Patients homozygous for the TS 1494del6 (0/0 bp) experienced statistically higher OMI scores (440%) compared to individuals without the deletion (Po0.01, Table 2 ). No differences in OMI were observed by TSER genotype. In the analysis of combined TS genotypes, the increase associated with the 0/0 bp genotype was still present, although not statistically significant perhaps due to a smaller number of patients in each cell. We also investigated whether OMI during days 6-12 showed similar patterns, and results were similar for both MTHFR and TS genotypes.
Variation in the relative availability of intracellular folate as a result of genetic variation in the MTHFR and TS enzymes may alter the degree of early post transplant oral mucositis experienced by HCT patients receiving MTX. This study supports our initial findings and other reports of a modification of MTX toxicity by MTHFR genotypes, 2,7-10 and suggests that the TS 1494del6 polymorphism may also alter MTX-associated toxicity. Tailoring of MTX dosing for the prevention of graft-versus-host disease among HCT patients could be considered if drug efficacy is not adversely affected. 
